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Abstract. In 2006 the U.S. Agency for International Development (USAID) established the Neglected Tropical
Disease (NTD) Control Program to support national governments in developing successful, cost-efficient NTD programs
that integrate disease-specific programs into coordinated national initiatives, in accord with the World Health Organiza-
tion recommendations. A 3-stage “roll-out package” has been developed for effectively integrating and scaling up such
programs to full-national scale. Stage-1 lays the groundwork—identifying NTD leadership within the Ministry of Health,
conducting a national Situation Analysis, formulating a multiyear Plan of Action, and undertaking a funding gap analysis.
Stage-2 focuses on scaling up the integrated NTD program—convening national stakeholder meetings, developing
annual work plans, carrying out disease mapping, and establishing monitoring and evaluation activities. Stage-3 aims at
ensuring effective management—identifying clear roles and responsibilities for partners, and creating a central coordi-
nating mechanism. Assessment and reassessment of these complex NTD programs that target literally billions of people
are essential to establish “best practice” strategies for long-term public health success.
INTRODUCTION
In recent years, the World Health Organization (WHO)
has promoted the concept of integrated preventive chemo-
therapy (PCT) as the principal strategy for control or elimina-
tion of a group of seven debilitating infections recognized
as neglected tropical diseases (NTDs)—lymphatic filariasis
(elephantiasis), onchocerciasis (river blindness), schistosomia-
sis (snail fever),three soil-transmitted helminthiases (causedby
Ascaris, Trichuris, and hookworm), and blinding trachoma.
1
These diseases affect more than 2 billion people in the devel-
oping world, with many suffering simultaneously from multiple
NTDs. With diagnostic and treatment tools that are effective,
easy to use, and available at minimal or no cost, these NTDs
are now considered by WHO to be “tool-ready” and are
targeted for control or elimination through a number of
large-scale global health initiatives supported through WHO’s
coordination and programmatic guidance.
1,2
Underpinning most of these initiatives are enormous dona-
tions from private sector pharmaceutical companies
3–7 of the
specific medications that can be used to treat each disease
safely, simply, and effectively through large-scale PCT. The
treatment regimens vary from administration once or twice per
year to once every 2 years, given either to entire populations
at-risk for the disease(s) (i.e., mass drug administration [MDA])
or targeted to specific at-risk groups, such as school-age chil-
dren or specific occupational groups. Although it is unques-
tioned that these donations† are absolutely necessary for the
current global initiatives, it is also important to recognize that
the donations alone are not sufficient. There must be two addi-
tional, essential spheres of partnership: first, with the minis-
tries of health (MOHs) of the affected countries who, together
with other public sectors (e.g., education), take responsibility
for responding to the very great public health challenge of
reaching and treating all the targeted at-risk populations; and
second, with funding and technical assistance that can aid the
ministries to carry out these programs in countries with insuf-
ficient domestic resources to address these challenges alone.
A principal source of this external funding support in recent
years has been the U.S. Agency for International Develop-
ment (USAID). In 2006, USAID established the NTD Control
Program, implemented by RTI International, with the expressed
purpose of supporting national governments to develop suc-
cessful, cost-efficient NTD control programs that integrate
or bundle their disease-specific programs into coordinated
initiatives and then to link these programs effectively with
other elements of their established national health delivery
systems. The achievements of the first seven countries partici-
pating in this USAID-supported NTD Control Program during
its first 3 years have been reviewed in detail.
8 Table 1 summa-
rizes key quantitative elements from that earlier description
with more current, updated information that includes the
NTD Control Program’s fourth year. Although these results
can be recognized as only output measures not yet trans-
lated into impact measures—which are of greatest impor-
tance to health and economic development in these affected
countries—still it is clear that by any standard, the accomplish-
ments of these national NTD control programs after just a few
years of operation are both remarkable and commendable.
It should not be surprising, however, that the accomplish-
ments of these national programs did not come easily or
without challenges. Indeed, many lessons were learned over
time as good practices became better, better practices became
best practices, and best practices improved and evolved into
evidence-based policy that can be shared across countries.
Because the expansion of integrated national NTD control
programs worldwide is still in its infancy, and since many
more countries still need to begin their programmatic activi-
ties, this report is meant to capture the early experiences of
countries introducing and/or scaling up integrated NTD activ-
ities during the NTD Control Program’s first 4 years and to
*Address correspondence to Eric A. Ottesen, RTI International,
701 13th Street NW, Suite 750, Washington, DC 20005-2230. E-mail:
eottesen@rti.org
†Albendazole (GlaxoSmithKline, Brentford, Middlesex, UK);
Azithromycin [Zithromax] (Pfizer, New York, NY); Ivermectin
[Mectizan] (Merck & Co., Inc. Whitehouse Station, NJ); Mebendazole
(Johnson & Johnson, New Brunswick, NJ, USA); Praziquantel (Merck-
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508identify practices that are now appreciated as successful stra-
tegic approaches (or best practices) for developing and rolling
out integrated NTD control programs at full national scale.
It also documents how a learning agenda, generation of
evidence, and programmatic refinement have been used by
WHO and its partners to shape global health policy.
METHODS
The USAID has supported the implementation of inte-
grated programs targeting NTDs in 13 countries through the
NTD Control Program. A detailed description of the Program
has been presented previously,
8 but a number of program ele-
ments need special emphasis because of their demonstrated
importance and applicability in specific settings, their program-
matic benefits and efficiency gains, and their influence on the
structure and operational approaches of the national NTD
control programs being supported.
Aims of the NTD Control Program. The stated aims of the
NTD Control Program reflect the intent of USAID to support
national governments in their roles as the stewards of NTD
programs. Specifically, the Program’s principal aims from
the beginning have been to 1) support and empower national
governments to develop integrated NTD control programs
embedded, where possible, within existing service delivery
platforms and to scale up these programs to full national level;
2) provide technical assistance for planning, budgeting, and
reporting; 3) promote cost-efficiency; and 4) ensure national
ownership, continued commitment, and resource mobiliza-
tion for sustained support for NTD control.
Participating countries. Countries currently participating
in the NTD Control Program are identified in Table 2, along
with the principal nongovernmental organizations (NGOs)
supporting them. The first five countries (Burkina Faso,
Ghana, Mali, Niger, and Uganda) were selected because they
already had pilot programs in place for integrated control of
NTDs that had been sponsored as operational research stud-
ies by The Bill and Melinda Gates Foundation and by the
U.K.’s Department for International Development through
the Liverpool NTD Support Center. Because scaling up to fully
national programs was a stated goal of the NTD Control Pro-
gram, these countries were able to take immediate advantage
of additional program resources to support scale-up activ-
ities. Additional countries have come into the program pro-
gressively, so that by the end of the Program’s fourth year,
13 countries were included, 10 of which had already begun
implementation of their yearly USAID-supported MDA
activities. It is from these 13 countries that the lessons learned
and best practices described below were derived.
Operations, standards, and metrics. Countries were sup-
ported for only those operations and technical strategies fully
in line with recommendations and guidelines provided by
WHO.
2,8 Where global guidance for aspects of implementing
integrated programs was lacking, the NTD Control Program
developed and tested new tools and approaches in consulta-
tion with national programs and WHO. For example, a com-
mon monitoring and evaluation (M&E) framework to support
integrated implementation was absolutely essential for pro-
gram success and needed to be developed on a common plat-
form for maximal usefulness. Such a platform was developed
collaboratively by the national programs, NGOs, NTD Con-
trol Program, and WHO, and it has been used in nationally
scaled programs.
9 The principal metrics assessed are those
identified in Table 1.
RESULTS
During the first 4 years of NTD Control Program opera-
tions, there were many lessons learned. As a practical out-
come, the Program developed and refined, in concert with its
partners, a strategy and supporting tools for initiating and
sustaining integrated NTD country programs. The strategy
reflects consensus on a sequence of important steps and activi-
ties that lead to well-designed, government-led, cost-effective,
Table 1
NTD control program output metrics: years 1–4
Indicator Year 1 Year 2 Year 3 Year 4 Cumulative 4-year total
Number of countries beginning MDA programs each year with
USAID support 4 1 2 3 10
Number of persons treated each year with USAID support 16,339,325 27,638,323 55,894,206 70,001,700 169,873,553*
Number of treatments provided each year with USAID support 36,816,157 58,029,384 129,200,566 165,412,570 389,458,677*
Number of districts newly treated each year with USAID support 106 52 169 287 614
Program coverage (persons treated/persons targeted—range
across all drug packages each year) 69–100% 57–97% 62–100% 64–100% 57–100%
Value of drugs donated each year to NTD Control
Program countries $404 million $507 million $577 million $686 million $2.174 billion
Number of workers in training programs supported by USAID
each year 107,269 158,731 221,412 389,214 876,626*
*Includes people treated (or trained) more than one time during the four years.
NTD = neglected tropical disease; MDA = mass drug administration; USAID = U.S. Agency for International Development.
Table 2
NTD Control Program: years 1–4
County Lead NGO
Bangladesh* RTI International
Burkina Faso Schistosomiasis Control Initiative
Cameroon Helen Keller International
Ghana World Vision
Haiti IMA-World Health
Mali Helen Keller International
Nepal* RTI International
Niger Schistosomiasis Control Initiative
Sierra Leone Helen Keller International
Southern Sudan Malaria Consortium
Tanzania* IMA-World Health
Togo Health and Development International
Uganda RTI International
*MDA activities supported by NTD Control Program not yet started by Year 4.
NTD = neglected tropical disease; NGO = nongovernmental organization.
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sequence has been termed the roll-out package and consists
of three principal stages:
1. laying the groundwork;
2. rolling out an integrated program; and
3. establishing effective management.
The utility and technical soundness of this package have
recently been acknowledged through endorsement of WHO’s
Strategic and Technical Advisory Group (STAG) as the roll-
out package for global use.‡ This endorsement facilitates access
to proven NTD strategies and tools for countries beyond those
that can be supported by USAID, and through spreading the
efficiency gains, can stimulate expansion of NTD control
efforts globally.
Stage 1: Laying the groundwork. Ensuring commitment by
the national government is likely the most important element
for both short- and long-term success of a national NTD con-
trol program. Indeed, it is an aspect of the roll-out package
that needs to be addressed, not just at the earliest stage of
program development, but at every opportunity where rein-
forcement is possible. Its measures are not just the financial
or personnel contributions of the government but also the
commitment to reorganizing management structures to ensure
effective, integrated NTD control programs. A principal indi-
cator of such commitment, assessed by the NTD Control Pro-
gram, is the designation of a point person within either the
MOH or ministry of education (MOE) who will coordinate
activities of the individual NTD control programs and lead an
integrated approach to their control. Sustained and/or increas-
ing levels of investment by the government is another marker
for which measuring tools have been developed (discussed
below). Commitment is also demonstrated through documen-
tation of the country’s NTD problems, of a strategic national
plan to address these problems, and of an appreciation of the
cost of carrying out this plan.
The Country Situation Analysis Tool is used to compile and
define the country’s NTD problems. This analysis provides
a detailed, up-to-date, standardized account of the available
evidence for the prevalence of NTDs and for specific control
activities and any related research ongoing in the country. Such
an analysis is an essential first step for planning integrated
activities and is particularly valuable in defining a baseline
for stakeholders during the early planning for integration—
defining gaps in available information and activities, advocat-
ing for donor support, and identifying potential partners for
implementation, technical assistance, and operational research.
Ideally, the analysis is prepared by a team of local, disease-
specific experts and academics, thereby engaging a cadre of
local technical stakeholders early in the process and encour-
aging their involvement in program planning at the earliest
stages. Although the situation analysis can be time consuming
to develop, having accurate and complete information and
engaged local expertise results in significant time-savings and
efficiencies at later stages in the process of program startup.
A multiyear National Plan of Action (POA or “Master
Plan”), recognizing the NTD challenges and potential plat-
forms on which integrated programs can be launched, must
be formulated to prioritize and address these diseases. Once
the situation analysis is complete, it will be clear that there are
some areas where program implementation can begin imme-
diately and others where additional NTD prevalence infor-
mation (e.g., disease mapping) is necessary. Thus, the initial
POA must include the progressive roll out of both these sets
of program activities; and, as mapping is completed, the national
POA must be updated appropriately. Such a POA should be
developed by the government with its stakeholders and key
partners in NTD control and with full engagement by WHO,
which has created a standardized framework for these plans.
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A national POA that documents a rational and comprehen-
sive approach is essential for coordinated action at the coun-
try level and is also the basis for determining the program’s
funding needs.
A funding gap analysis is needed for identifying costs for
the NTD program envisioned in the national POA. A specific
tool (described in detail elsewhere
12) to analyze the costs and
needs of integrated NTD control programs was developed by
the NTD Control Program to provide standardized detailed
quantification of the costs for implementing integrated NTD
control activities in line with international guidelines, with the
country’s national plan, and with existing resources available
from the government and other donors. This tool is partic-
ularly valuable for ensuring recognition of the contributions
that governments make toward their national NTD control by
quantifying their inputs of largely in-kind resources, such as
staff time, materials, and health system infrastructure. Once
the funding gap is identified for NTD interventions, country
programs and potential donors can be provided with clear
information about what is required to achieve the national
program’s goals for NTD elimination or control. The Funding
Gap Analysis Tool empowers governments to coordinate the
various donor inputs in support of a comprehensive plan and
budget. It provides an essential base for scale-up plans and
resource allocation and serves as a valuable tracking tool for
documenting opportunities for cost-efficiencies and govern-
ment commitment over time.
Stage 2: Scaling up an integrated NTD program. Ideally,
a country’s comprehensive integrated NTD control program
would begin its roll out with all the preliminary groundwork
completed. In reality, of course, that simply does not happen,
as many groundwork and roll-out activities are carried out
simultaneously. Regardless of whether they are carried out
simultaneously or sequentially, there are a number of key
elements that can be identified for the successful roll out of
any national NTD program.
Meetings of national stakeholders. To present and refine
both the POA (based on the situation analysis) and the results
of the funding gap analysis, a meeting of all stakeholders—
including the drug donation programs and other potential
donors—should be convened by the MOH, and, when appro-
priate, in concert with the MOE. The WHO support for these
meetings is very valuable for endorsing technical decisions.
The stakeholders meeting is an important opportunity to pro-
vide a transparent presentation of funding requirements, roles
and responsibilities, and program scale-up targets to all con-
cerned parties. Government leadership is reaffirmed as dis-
cussions of how to address the existing financial and technical
‡“STAG recognizes the package of programmatic and M&E tools
jointly developed by WHO and NTD partners as current best prac-
tice; and recommends that WHO formally adopt this package to roll
out preventive chemotherapy interventions...and operationalize M&E
tools in a regional context.”10
510 HANSON AND OTHERSgaps are viewed in the context of a broader national program.
Deliberate assessment of the capacities of all partners to con-
tribute to a POA, along with identification of all possible
existing service delivery platforms (e.g., schools, child health
days) on which the program could be based, can yield effi-
ciencies for scale up by not requiring costly new infrastruc-
ture or networks. Such inclusive consultation can stimulate
the willingness of partners to expand their activities, such as
adding delivery of an additional drug to a previously single-
disease project, to support the national scale up of an inte-
grated approach. Even in settings where partners already
have strong working relationships, the stakeholders meetings
held regularly enhance these partnerships among the various
levels of government ministries and with other implementing
partners. Most country programs have institutionalized annual
stakeholders meetings both to report back to partners on
program results and to review the annual work plan.
Annual work plan development. Ideally, stakeholders
reconvene each year to develop a detailed annual work plan
and budget. The process of developing the plan reinforces
integrated planning grounded in an understanding of the chal-
lenges and successes of the previous year, encourages joint
discussions about where cost-efficiencies can be made, improves
understanding of the requirements and priorities of individual
disease programs, and produces a detailed plan and budget to
which the entire team can commit. Modifications of the POA
or changes in the NTD funding gap that bear on the imple-
mentation activities and strategy can also be accommodated
during these annual work plan sessions.
Disease mapping. For countries to plan for implementation
most effectively and to apply for essential drugs, the endemic
NTDs must be mapped accurately.§ In many countries, map-
ping for one or more diseases is not complete so that national
implementation scale up cannot be accurately planned for or
budgeted. Determining the extent of disease burden and dis-
tribution is a critical initial step for all country programs. The
need for disease mapping should be clearly defined, begin-
ning with the situation analysis and then progressively under-
taken according to the guidelines from WHO and the drug
donation programs.
Monitoring and Evaluation. The NTD Control Program
developed a system for simple, standard integrated monitor-
ing of results that can be adapted and implemented in each
country setting—tracking disease-specific treatment goals and
integration indicators for total population treated, population
coverage rates, and combined treatments provided.
9 With this
system, managers and donors have prompt, regular semi-
annual reports on progress toward goals (by country and disease
target) that can be shared with district-level stakeholders, and
between country programs, as appropriate. Any program-
matic weaknesses, such as low uptake of drugs during MDA
campaigns, can be quickly identified and addressed to ensure
public health progress. Integrated reporting and monitoring
forms have facilitated the ability of individual program man-
agers to understand the requirements of all the endemic
NTDs and have encouraged joint participation by disease-
specific program managers in the monitoring process.
Stage 3: Establishing effective management.
Establishing clear roles and responsibilities. The challenges
inherent in combining (or even just coordinating) multiple
disease-specific programs in a country are all too obvious.
Therefore, developing consensus on managerial arrangements
is essential—first, within the national government (notably
between the MOE and MOH) about how the leadership of a
national NTD program will be defined (including the specific
roles of each government entity); and second, among the
partners with respect to their roles, responsibilities, and
intended contributions toward national NTD control efforts.
Although an agreed POA and successful stakeholder meet-
ings are important steps in defining these roles, clarification of
the flow of funds and the associated responsibilities is also
essential. Indeed, the degree of transparency (i.e., understand-
ing) of this flow of funds and responsibilities is often a princi-
pal driver of the effectiveness with which the partnership
functions. It, therefore, deserves appreciable attention.
Central coordinating mechanism A central-level coordinat-
ing mechanism, such as a steering committee that includes
disease-specific program managers (i.e., an NTD Task Force),
has proven invaluable in providing a critical forum for plan-
ning, problem resolution, and advocacy within the country.
The significant challenges of integrating strong and inde-
pendent disease-specific programs can be overcome through
strong leadership by a higher level government colleague who
can mobilize the efforts of a team of previously independent
program managers to achieve rapid, cost-effective integration.
Central coordinating mechanisms, meeting 2–4 times per year,
have been institutionalized in all implementing countries as a
means of ensuring representation for all appropriate disease-
specific programs, and for other government stakeholders,
especiallytheMOE.
DISCUSSION
The challenge of integrating multiple disease-specific con-
trol programs—here interpreted primarily as enabling pro-
grams to carry out similar activities in a most efficient and
cost-effective manner—is one that has been taken up enthusi-
astically by WHO and the national programs supported by the
USAID NTD Control Program.
1,8,14–18 Because past experi-
ence with such integration was largely anecdotal, it was one
of the principal aims of the NTD Control Program to iden-
tify empirically the most effective and efficient strategies that
could later be used to inform other programs also seeking
to integrate their NTD activities. The enormous challenges
facing the establishment of successful national scale MDA
programs have recently been emphasized, along with the impor-
tance of careful monitoring to ensure their effectiveness.
19–21
Indeed, it can only be through repeated examination of such
programs—the efforts made, lapses identified, and remedies
attempted—that better and better practices will be identified.
Although defining the very best strategies for initiating these
integrated programs might still lie in the future, the experi-
ences from more than a dozen countries during the NTD Con-
trol Program’s first four years have given clear indications
both of what works well and of what likely pitfalls might appear
in the start-up phase of these national programs. The recent
endorsement of the resulting NTD roll-out package by WHO’s
§As described in WHO guidelines,
13 program-oriented mapping is
not “prevalence mapping,” but “action mapping” that provides a
geographic depiction of what needs to be done for integrated NTD
control (i.e., which drug packages to be administered) at each district
(or other subunit) throughout the country.
ROLL OUT OF NTD PROGRAMS AT NATIONAL SCALE 511NTD Scientific and Technical Advisory Group
10 is a strong
acknowledgment of the evidence base for this emerging approach
and the optimism for its long-term success.
Box 1 summarizes the components of what today is con-
sidered the most effective roll-out strategy. These elements
and, to a lesser degree, the order in which they are instituted
are essential for creating effective and efficient integrated
programs targeting the NTDs. There are many instances that
could be cited where failure to attend to one or more of these
essential elements early in the roll-out process—i.e., having
a lack of sufficient government commitment, a poor under-
standing of disease distribution, an inadequate assessment of
funding needs, poorly engaged stakeholders, an imprecise
work plan, and the like—have caused programs to falter ini-
tially. The details of some of these failures and the reme-
dies applied have been previously recorded,
15,18–21 and other
accounts will follow from subsequent country reports. The
purpose of this work, however, has been to summarize the
key lessons learned from these early experiences and to define
what appears today to be the most effective roadmap to suc-
cessful program development. This roll-out strategy pro-
vides a strong foundation for the complex partnerships among
private- and public-sector organizations that must thrive and
be sustained for these programs to succeed. As this roll-out
package has evolved in concert with WHO’s NTD Control
Department, it also reflects its current approach to integrated
control of the seven tool-ready NTDs
1 that are targeted through
PCT using the technique of large-scale mass or targeted drug
administration. Because MDA can be extremely complex and
diverse in its organization—both within and across individual
countries—it is essential that the roll-out strategy leading to
it provides for well-grounded, solid, and fully supportive part-
nerships to ensure long-term program success.
Such partnering in support of national NTD programs by
USAID now falls conceptually within the U.S. Government’s
recently defined Global Health Initiative (GHI
22) whose
principal emphases—on gender equality, country ownership,
strengthening health systems, promoting partnerships, foster-
ing coordination and integration, improving M&E, and pro-
moting innovation—are all fully consonant with those of the
NTD roll-out strategy. Overall, the roll-out strategy represents
a strong focus on host-country government ownership and
leadership. Furthermore, the success of the first 4 years of
the NTD Control Program clearly reflects the very important
GHI goal of innovation for success. Indeed, the next phase
of the NTD Control Program—including both expanding to
additional countries and quantifying program impact on the
broader measures of societal health, education, and economics—
will not only further strengthen the evidence base for optimiz-
ing integrated control of the NTDs but, at the same time, will
fully support the more expansive goals and targets of both the
GHI and the similar bilateral and multinational initiatives
in global health currently being undertaken or anticipated.
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